Showing results (201-210 of 259) with videos related to
Sort By:
Pageof 26
Leukemia & Lymphoma|December 18, 2019
1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomibChenxing Du, Xuehan Mao, Yan Xu, et al.The Oncologist|March 10, 2025
Classification of NK-large granular lymphocytic leukemia by CD56 expressionYuxi Li, Rui Cui, Ying Yu, et al.Journal for Immunotherapy of Cancer|September 13, 2022
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaXiaoyan Qu, Gang An, Weiwei Sui, et al.BMC Medicine|April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyLugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.Cancer Medicine|March 14, 2018
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 studyXiaojun Huang, Lugui Qiu, Jie Jin, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 22, 2023
Clinical characteristics and outcomes of follicular lymphoma patients with extranodal involvement: analysis of a series of 1090 cases in ChinaZhijuan Lin, Jie Zha, Shuhua Yi, et al.American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.Blood Advances|June 11, 2024
Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapiesShuhui Deng, Sanika Derebail, Vera Joy Weiler, et al.Journal of Hematology & Oncology|September 7, 2020
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemiaRunxia Gu, Fang Liu, Dehui Zou, et al.Pageof 26